The DOI matches its Crossref record; 377 of the 377 references it cites were found in a registry or an index.
Targeting Transcription Factors for Cancer Treatment
Open accessAbstract
Transcription factors are involved in a large number of human diseases such as cancers for which they account for about 20% of all oncogenes identified so far. For long time, with the exception of ligand-inducible nuclear receptors, transcription factors were considered as “undruggable” targets. Advances knowledge of these transcription factors, in terms of structure, function (expression, degradation, interaction with co-factors and other proteins) and the dynamics of their mode of binding to DNA has changed this postulate and paved the way for new therapies targeted against transcription factors. Here, we discuss various ways to target transcription factors in cancer models: by modulating their expression or degradation, by blocking protein/protein interactions, by targeting the transcription factor itself to prevent its DNA binding either through a binding pocket or at the DNA-interacting site, some of these inhibitors being currently used or evaluated for cancer treatment. Such different targeting of transcription factors by small molecules is facilitated by modern chemistry developing a wide variety of original molecules designed to specifically abort transcription factor and by an increased knowledge of their pathological implication through the use of new technologies in order to make it possible to improve therapeutic control of transcription factor oncogenic functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–377 of 377
Kirschbaum, M. H., Foon, K. A., Frankel, P. H., Ruel, C., Pulone, B., Tuscano, J. M., & Newman, E. M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.877134 · Cited by 74
BCL6 promotes glioma and serves as a therapeutic target
Xu, L., Chen, Y., Dutra‐Clarke, M., Mayakonda, A., Hazawa, M., Savinoff, S. E., Doan, N., SAID, J. W., Yong, W. H., Watkins, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609758114 · Cited by 74
Acute Promyelocytic Leukemia: A Paradigm for Differentiation Therapy
Grimwade, D. J., Mistry, A. R., Solomon, E., & Guidez, F. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_13 · Cited by 72
Vilaboa, N. E., Boré, A., Martin-Saavedra, F., Bayford, M., Winfield, N., Firth‐Clark, S., Kirton, S. B., & Voellmy, R. W. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx194 · Cited by 72
Inhibition of p53-mediated transcriptional responses by mithramycin A
Koutsodontis, G., & Kardassis, D. (2004) · Oncogene · doi:10.1038/sj.onc.1208141 · Cited by 71
Sequence-specific DNA binding Pyrrole–imidazole polyamides and their applications
Kawamoto, Y., Bando, T., & Sugiyama, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.026 · Cited by 71
Allosteric Inhibition of Protein−DNA Complexes by Polyamide−Intercalator Conjugates
Fechter, E. J., & Dervan, P. B. (2003) · Journal of the American Chemical Society · doi:10.1021/ja030125e · Cited by 70
Izetti, P., Hautefeuille, A. H., Abujamra, A. L., de Farias, C. B., Giacomazzi, J., Alemar, B., Lenz, G., Roesler, R., Schwartsmann, G., Osvaldt, A. B., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0090-9 · Cited by 70
CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells
Delehouzé, C., Godl, K., Loaëc, N., Bruyère, C., Desban, N., Oumata, N., Galons, H., Roumeliotis, T. I., Γιαννοπούλου, Ε., Grenet, J. A., et al. (2013) · Oncogene · doi:10.1038/onc.2013.513 · Cited by 70
A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein
Pop, M. S., Stransky, N., Garvie, C. W., Theurillat, J.-P. P., Hartman, E. C., Lewis, T. A., Zhong, C. F., Culyba, E. K., Lin, F., Daniels, D. S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0689 · Cited by 70
Brach, D., Johnston-Blackwell, D., Drew, A., Lingaraj, T., Motwani, V., Warholic, N. M., Feldman, I., Plescia, C., Smith, J. J., Copeland, R. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0840 · Cited by 70
Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Loosveld, M., Castellano, R., Gon, S., Goubard, A., Crouzet, T., Pouyet, L., Prébet, T., Vey, N., Nadel, B., Collette, Y., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1873 · Cited by 69
Munde, M., Wang, S., Kumar, A., Stephens, C. E., Farahat, A. A., Boykin, D. W., Wilson, W. D., & Poon, G. M. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt955 · Cited by 68
Dillon, M., Bachovchin, D. A., Brown, S. J., Finn, M. G., Rosen, H., Cravatt, B. F., & Mowen, K. A. (2012) · ACS Chemical Biology · doi:10.1021/cb300024c · Cited by 68
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Li, J., Cai, J., Zhao, S., Yao, K., Sun, Y., Li, Y., Chen, L., Li, R., Zhai, X., Zhang, J., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0463-3 · Cited by 68
Insulin Induces REDD1 Expression through Hypoxia-inducible Factor 1 Activation in Adipocytes
Regazzetti, C., Bost, F., MARCHAND‐BRUSTEL, Y. L., Tanti, J., & Giorgetti‐Peraldi, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047688 · Cited by 67
Xu, S., Aguilar, A., Xu, T., Zheng, K., Huang, L., Stuckey, J. A., Chinnaswamy, K., Bernard, D., Fernández‐Salas, E., Liu, L., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201711828 · Cited by 67
The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis
Gao, Y., & Ge, W. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0040-5 · Cited by 67
Fransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies
Matthews, G. M., Mehdipour, P., Cluse, L. A., Falkenberg, K. J., Wang, E., Roth, M., Santoro, F., Vidacs, E., Stanley, K. L., House, C. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-632984 · Cited by 65
GLI2 is a novel therapeutic target for metastasis of osteosarcoma
Nagao‐Kitamoto, H., Nagata, M., Nagano, S., Kitamoto, S., Ishidou, Y., Yamamoto, T., Nakamura, S., Tsuru, A., Abematsu, M., Fujimoto, Y., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29107 · Cited by 63
Yan, R., Peng, X., Yuan, X., Huang, D., Chen, J., Lu, Q., Lv, N., & Luo, S. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0149-1 · Cited by 62
Lee, Y. K., Isham, C. R., Kaufmann, S. H., & Bible, K. C. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0235 · Cited by 62
Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells
Fowler, T., Ghatak, P., Price, D. H., Conaway, R., Conaway, J. W., Chiang, C., Bradner, J. E., Shilatifard, A., & Roy, A. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087003 · Cited by 61
p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
Krayem, M., Journé, F., Wiedig, M., Morandini, R., Najem, A., Salès, F., van Kempen, L. C. L. T., Sibille, C., Awada, A. H., Marine, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.002 · Cited by 61
Deben, C., Lardon, F., Wouters, A., de Beeck, K. O., den Bossche, J. V., Jacobs, J., Steen, N. V. D., Peeters, M., Rolfo, C. D., Deschoolmeester, V., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.017 · Cited by 61
LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis
Ashkar, S. E., Schwaller, J., Pieters, T., Goossens, S., Demeulemeester, J., Christ, F., Belle, S. V., Juge, S., Boeckx, N., Engelman, A., et al. (2017) · Blood · doi:10.1182/blood-2017-05-786962 · Cited by 61
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
Zhang, Z., Ding, Q., Liu, J.-J., Zhang, J., Jiang, N., Chu, X.-J., Bartkovitz, D., Luk, K.-C., Janson, C., Tovar, C., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.072 · Cited by 60
Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development
Buettner, R., Corzano, R., Rashid, R., Lin, J., Senthil, M., Hedvat, M., Schroeder, A., Mao, A., Herrmann, A., Yim, J. H., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb100253e · Cited by 60
SOXF transcription factors in cardiovascular development
Lilly, A. J., Lacaud, G., & Kouskoff, V. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.07.021 · Cited by 60
Malek, A. V., Núñez, L. E., Magistri, M., Brambilla, L., Jovic, S., Carbone, G. M., Morís, F., & Catapano, C. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035130 · Cited by 59
Kamada, Y., Sakai, N., Sogabe, S., Ida, K., Oki, H., Sakamoto, K., Lane, W., Snell, G., Iida, M., Imaeda, Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00313 · Cited by 57
Chiang, S.-Y., Azizkhan, J. C., & Beerman, T. A. (1998) · Biochemistry · doi:10.1021/bi9721142 · Cited by 56
Peixoto, P., Liu, Y., Depauw, S., Hildebrand, M., Boykin, D. W., Bailly, C., Wilson, W. D., & David‐Cordonnier, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn208 · Cited by 56
Self-citationSpecific Blocking of CREB/DNA Binding by Cyclometalated Platinum(II) Complexes
Wang, P., Leung, C., Ma, D., Sun, R. W., Yan, S., Chen, Q., & Che, C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201006887 · Cited by 56
Modulation of Hoogsteen dynamics on DNA recognition
Xu, Y., McSally, J., Andricioaei, I., & Al‐Hashimi, H. M. (2018) · Nature Communications · doi:10.1038/s41467-018-03516-1 · Cited by 55
Hansen, M. R., Yun, S., & Hurley, L. H. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90273-2 · Cited by 54
Zhang, J., Zhang, H., Wang, H., Li, Y.-X., Liu, G.-H., Xing, S., Li, M.-Z., & Zeng, M. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0222-1 · Cited by 54
The Sp family of transcription factors in the regulation of the human and mouse MUC2 gene promoters.
Aslam, F., Palumbo, L., Augenlicht, L. H., & Velcich, A. (2001) · PubMed · Cited by 54
Li, D., Chen, W., Wang, Z., Xie, Y.-Y., Xu, X., Jiang, Z., Zhang, X., You, Q., & Guo, X. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.036 · Cited by 53
RUNX transcription factors at the interface of stem cells and cancer
Deltcheva, E. M., & Nimmo, R. A. (2017) · Biochemical Journal · doi:10.1042/bcj20160632 · Cited by 53
Canesin, G., Axelsson, S. E., Hellsten, R., Sterner, O., Krzyzanowska, A., Andersson, T., & Bjartell, A. S. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.016 · Cited by 51
Sharma, A. K., Ray, R., & Rajeswari, M. R. (2008) · Cancer Investigation · doi:10.1080/07357900801954210 · Cited by 51
Yasuda, D., Nakajima, M., Yuasa, A., Obata, R., Takahashi, K., Ohe, T., Ichimura, Y., Komatsu, M., Yamamoto, M. P., Imamura, R. M., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.083 · Cited by 50
Obinata, D., Takayama, K., Fujiwara, K., Suzuki, T., Tsutsumi, S., Fukuda, N., Nagase, H., Fujimura, T., Urano, T., Homma, Y., et al. (2016) · Oncogene · doi:10.1038/onc.2016.171 · Cited by 49
Bailly, C., Tardy, C., Wang, L., Armitage, B. A., Hopkins, K. T., Kumar, A., Schuster, G. B., Boykin, D. W., & Wilson, W. D. (2001) · Biochemistry · doi:10.1021/bi0108453 · Cited by 48
Soares, J., Espadinha, M., Raimundo, L., Ramos, H., Gomes, A. S., Gomes, S., Loureiro, J. B., Inga, A., Reis, F., Gomes, C. M. F., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12051 · Cited by 48
Bouhlel, M. S., Lambert, M., & David‐Cordonnier, M. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150413154713 · Cited by 47
Self-citationTargeting Notch degradation system provides promise for breast cancer therapeutics
Liu, J., Shen, J., Wen, X.-F., Guo, Y., & Zhang, G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.05.010 · Cited by 47
Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules
Zhang, W., Ma, T., Li, S., Yang, Y., Guo, J., Yu, W., & Kong, L. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.068 · Cited by 47
Genome-wide comparison of PU.1 and Spi-B binding sites in a mouse B lymphoma cell line
Solomon, L. A., Li, S. K. H., Piskorz, J., Xu, L., & DeKoter, R. P. (2015) · BMC Genomics · doi:10.1186/s12864-015-1303-0 · Cited by 46
Hong, S.-H., Youbi, S. E., Hong, S. P., Kallakury, B., Monroe, P. J., Erkizan, H. V., Barber-Rotenberg, J. S., Houghton, P. J., Üren, A., & Toretsky, J. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1495 · Cited by 46
Lü, J., McEachern, D., Li, S., Ellis, M. J., & Wang, S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0028 · Cited by 46
Petrovic, V., Costa, R. H., Lau, L. F., Raychaudhuri, P., & Tyner, A. L. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.12.11710 · Cited by 45
On the kinetics of distamycin binding to its target sites on duplex DNA
Baliga, R., & Crothers, D. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7814 · Cited by 45
Tsai, M.-H., Lin, Z., Liang, C., Yen, F., Chiang, Y., & Lee, C. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.06.012 · Cited by 45
Human Prostate Cancer Hallmarks Map
Datta, D., Aftabuddin, M., Gupta, D. K., Raha, S., & Sen, P. (2016) · Scientific Reports · doi:10.1038/srep30691 · Cited by 45
Kurebayashi, J., Koike, Y., Ohta, Y., Saitoh, W., Yamashita, T., Kanomata, N., & Moriya, T. (2017) · Cancer Science · doi:10.1111/cas.13205 · Cited by 45
Yang, L., Liu, L., Gao, H., Pinnamaneni, J. P., Sanagasetti, D., Singh, V., Wang, K., Mathison, M. N., Zhang, Q., Chen, F., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0531-y · Cited by 45
Guo, S., Luo, W., Liu, L., Pang, X., Zhu, H., Liu, A., Lu, J., Ma, D., Leung, C., Wang, Y., et al. (2016) · Journal of drug targeting · doi:10.3109/1061186x.2016.1157882 · Cited by 44
Tong, W., Qiu, L., Meng, Q., Liu, J., Hu, K., Lin, W., Huang, Y., & Fu, J. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26572 · Cited by 44
Liu, R., Zhi, X., Zhou, Z., Zhang, H., Yang, R., Zou, T., & Chen, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-19489-6 · Cited by 44
Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells.
Yonekura, S., Itoh, M., Okuhashi, Y., Takahashi, Y., Ono, A., Nara, N., & Tohda, S. (2013) · PubMed · Cited by 43
Gonnissen, A., Isebaert, S. F., McKee, C. M., Dok, R., Haustermans, K. M., & Muschel, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.12483 · Cited by 42
Menin as a hub controlling mixed lineage leukemia
Thiel, A. T., Huang, J., Lei, M., & Hua, X. (2012) · BioEssays · doi:10.1002/bies.201200007 · Cited by 41
A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization
Xu, G. W., Mawji, I. A., Macrae, C. J., Koch, C. A., Datti, A., Wrana, J. L., Dennis, J. W., & Schimmer, A. D. (2008) · APOPTOSIS · doi:10.1007/s10495-007-0175-4 · Cited by 41
Grimley, E. C., Liao, C., Ranghini, E. J., Nikolovska‐Coleska, Z., & Dressler, G. R. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b00782 · Cited by 41
LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy
Zuo, M., Li, C., Lin, J., & Javle, M. M. (2015) · Oncotarget · doi:10.18632/oncotarget.3458 · Cited by 40
Yang, W., Song, M.-J., Park, E. Y., Lee, J.-J., Park, J., Park, K., Park, J. H., & Kim, H. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0191-x · Cited by 40
Bailly, C., Payet‐Bornet, D., TRAVERS, A. A., & Waring, M. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13623 · Cited by 40
Site-Specific Inhibition of Transcription Factor Binding to DNA by a Metallointercalator
Odom, D. T., Parker, C. S., & Barton, J. K. (1999) · Biochemistry · doi:10.1021/bi9827969 · Cited by 40
Is Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer
Trop-Steinberg, S., & Azar, Y. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.06.007 · Cited by 40
Yu, X., He, L., Cao, P., & Yu, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128406 · Cited by 39
D’Angelo, D., Borbone, E., Palmieri, D., Uboldi, S., Esposito, F., Frapolli, R., Pacelli, R., D’Incalci, M., & Fusco, A. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.014 · Cited by 39
ORY-1001: Overcoming the Differentiation Block in AML
Bose, P., & Konopleva, M. Y. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.014 · Cited by 39
HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype
Monterisi, S., Riso, P. L., Russo, K., Bertalot, G., Vecchi, M., Testa, G., Fiore, P. P. D., & Bianchi, F. (2018) · Oncogene · doi:10.1038/s41388-018-0229-9 · Cited by 39
Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors
Pallandre, J., Borg, C., Rognan, D., Boibessot, T., Luzet, V., Yesylevskyy, S. O., Ramseyer, C., & Pudlo, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.054 · Cited by 38
Yasui, T., Yamamoto, T., Sakai, N., Asano, K., Takai, T., Yoshitomi, Y., Davis, M., Takagi, T., Sakamoto, K., Sogabe, S., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.07.037 · Cited by 38
Targeted Suppression of EVI1 Oncogene Expression by Sequence-Specific Pyrrole-Imidazole Polyamide
Syed, J., Pandian, G. N., Sato, S., Taniguchi, J., Chandran, A., Hashiya, K., Bando, T., & Sugiyama, H. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.019 · Cited by 37
Escobar, Z., Bjartell, A. S., Canesin, G., Axelsson, S. E., Sterner, O., Hellsten, R., & Johansson, M. H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01814 · Cited by 37
p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
Nayak, S. K., Khatik, G. L., Narang, R., Monga, V., & Chopra, H. K. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170623111953 · Cited by 37
Meng, N., Tang, H., Zhang, H., Jiang, C., Su, L., Min, X., Zhang, W., Zhang, H., Miao, Z., Zhang, W., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.02.010 · Cited by 37
Peixoto, P., Bailly, C., & David‐Cordonnier, M. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-418-0_15 · Cited by 36
Self-citationTargeting a DNA Binding Motif of the EVI1 Protein by a Pyrrole–Imidazole Polyamide
Zhang, Y., Sicot, G., Cui, X., Vogel, M. J., Wuertzer, C. A., Lezon-Geyda, K., Wheeler, J., Harki, D. A., Muzikar, K. A., Stolper, D. A., et al. (2011) · Biochemistry · doi:10.1021/bi200962u · Cited by 35
Hou, C., Weidenbach, S., Cano, K. E., Wang, Z., Mitra, P., Ivanov, D. N., Rohr, J., & Tsodikov, O. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw761 · Cited by 35
Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship
Sakamoto, K., Sogabe, S., Kamada, Y., Sakai, N., Asano, K., Yoshimatsu, M., Ida, K., Imaeda, Y., & Sakamoto, J.-I. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.060 · Cited by 35
Untying the knot of transcription factor druggability: Molecular modeling study of FOXM1 inhibitors
Dakhili, S. A. T., Aguayo‐Ortiz, R., Domínguez, L., & Velázquez‐Martínez, C. A. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.01.009 · Cited by 35
Genomic Effects of Polyamide/DNA Interactions on mRNA Expression
Supeková, Ľ., Pezacki, J. P., Su, A. I., Loweth, C. J., Riedl, R., Geierstanger, B. H., Schultz, P. G., & Wemmer, D. E. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00174-6 · Cited by 34
p53 binds to cisplatin-damaged DNA
Wetzel, C. C., & Berberich, S. J. (2001) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00305-5 · Cited by 34
Binding Interaction of HMGB4 with Cisplatin-Modified DNA
Park, S., & Lippard, S. J. (2012) · Biochemistry · doi:10.1021/bi300649v · Cited by 34
Molecular and cellular processes underlying the hallmarks of head and neck cancer
Bernstein, J. M., Bernstein, C. R., West, C., & Homer, J. J. (2012) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-012-2323-x · Cited by 34
Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter
Grant, M. A., Baron, R. M., Macias, A. A., Layne, M. D., Perrella, M. A., & Rigby, A. C. (2008) · Biochemical Journal · doi:10.1042/bj20081427 · Cited by 34
AM-8553: A Novel MDM2 Inhibitor with a Promising Outlook for Potential Clinical Development
Bernard, D., Zhao, Y., & Wang, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3007068 · Cited by 34
Oladapo, H. O., Tarpley, M., Sauer, S. J., Addo, K., Ingram, S., Strepay, D., Ehe, B. K., Chdid, L., Trinkler, M., Roques, J., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.033 · Cited by 34
Heterozygous deletion of the PU.1 locus in human AML
Bonadies, N., Pabst, T., & Mueller, B. U. (2010) · Blood · doi:10.1182/blood-2009-03-212225 · Cited by 33
XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells
Liu, Y., Liu, A., Xu, Z., Yu, W., Wang, H., Li, C., & Lin, J. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0578-0 · Cited by 33
Brucoli, F., Hawkins, R. M., James, C., Jackson, P. J., Wells, G., Jenkins, T. C., Ellis, T., Kotecha, M., Hochhauser, D., Hartley, J. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001852 · Cited by 33
Yasuda, D., Yuasa, A., Obata, R., Nakajima, M., Takahashi, K., Ohe, T., Ichimura, Y., Komatsu, M., Yamamoto, M. P., Imamura, R. M., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.008 · Cited by 33
Nguyen-Hackley, D. H., Ramm, E. I., Taylor, C. M., Joung, J. K., Dervan, P. B., & Pabo, C. O. (2004) · Biochemistry · doi:10.1021/bi030223c · Cited by 32
Promoter Scanning for Transcription Inhibition with DNA-Binding Polyamides
Ehley, J. A., Melander, C., Herman, D., Baird, E. E., Ferguson, H. A., Goodrich, J. A., Dervan, P. B., & Gottesfeld, J. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1723-1733.2002 · Cited by 32
Shahi, M. H., Holt, R., & Rebhun, R. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096593 · Cited by 31
Baron, R. M., López-Guzmán, S., Riascos‐Bernal, D. F., Macias, A. A., Layne, M. D., Cheng, G., Harris, C. E., Chung, S. W., Reeves, R., von Andrian, U. H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010656 · Cited by 31
Taniguchi, M., Fujiwara, K., Nakai, Y., Ozaki, T., Koshikawa, N., Toshio, K., Kataba, M., Oguni, A., Matsuda, H., Yoshida, Y., et al. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.03.004 · Cited by 31
Munde, M. M., Poon, G. M. K., & Wilson, W. D. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.010 · Cited by 31
Kageyama, Y., Sugiyama, H., Ayame, H., Iwai, A., Fujii, Y., Huang, E. L., Kizaka‐Kondoh, S., Hiraoka, M., & Kihara, K. (2006) · Acta Oncologica · doi:10.1080/02841860500486648 · Cited by 30
A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression
Tian, H., Qian, G., Li, W., Chen, F., Di, J., Zhang, B., Pei, D., Ma, P., & Zheng, J. (2010) · Tumor Biology · doi:10.1007/s13277-010-0119-4 · Cited by 30
Abnormal Expression of the ERG Transcription Factor in Prostate Cancer Cells Activates Osteopontin
Flajollet, S., Tian, T. V., Flourens, A., Tomavo, N., Villers, A. A., Bonnelye, E., Aubert, S., Leroy, X., & Duterque‐Coquillaud, M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0537 · Cited by 30
Panobinostat for the treatment of acute myelogenous leukemia
Morabito, F., Voso, M. T., Hohaus, S., Gentile, M., Vigna, E., Recchia, A. G., Iovino, L., Benedetti, E., Lo‐Coco, F., & Galimberti, S. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1216971 · Cited by 30
How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
Steinhilber, D., & Marschalek, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.09.007 · Cited by 29
Transcription inhibition by Rh(phi)2(phen)3+
Fu, P. K. ‐., & Turró, C. (2001) · Chemical Communications · doi:10.1039/b007816f · Cited by 28
Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL
Ahmad, K. A., Katryniok, C., Scholz, B., Merkens, J., Löscher, D., Marschalek, R., & Steinhilber, D. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.39 · Cited by 28
Wu, J., Apontes, P., Song, L., Liang, P., Li, Y., & Li, F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm149 · Cited by 28
Ji, P., Xu, X., Ma, S., Fan, J., Zhou, Q., Mao, X., & Qiao, C. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00228 · Cited by 28
Munde, M. M., Kumar, A., Peixoto, P., Depauw, S., Ismail, M. A., Farahat, A. A., Paul, A., Say, M., David‐Cordonnier, M., Boykin, D. W., et al. (2014) · Biochemistry · doi:10.1021/bi401582t · Cited by 27
Self-citationAn Overview on Small Molecule Inhibitors of BRD4
Huang, W., Zheng, X., Yang, Y., et al. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557516666160611014130 · Cited by 27
Goossens, S., Peirs, S., Loocke, W. V., Wang, J., Takawy, M., Matthijssens, F., Sonderegger, S., Haigh, K., Nguyen, T. M., Vandamme, N., et al. (2017) · Blood · doi:10.1182/blood-2016-06-721191 · Cited by 27
Sameshima, T., Yamamoto, T., Sano, O., Sogabe, S., Igaki, S., Sakamoto, K., Ida, K., Gotou, M., Imaeda, Y., Sakamoto, J., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b00732 · Cited by 27
Sun, D., & Hurley, L. H. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90263-5 · Cited by 26
ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25–26;q22)
Moore, S. D. P., Offor, O., Ferry, J. A., Amrein, P. C., Morton, C. C., & Cin, P. D. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.10.014 · Cited by 26
Weber, A., Borghouts, C., Brendel, C., Moriggl, R., Delis, N., Brill, B., Vafaizadeh, V., & Groner, B. (2013) · Pharmaceuticals · doi:10.3390/ph6080960 · Cited by 26
Vizcaíno, C., Núñez, L. E., Morís, F., & Portugal, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104687 · Cited by 26
都築, 朋., Okada, H., Shindoh, H., Shimoi, K., Nishigaki, A., & Kanzaki, H. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1121225 · Cited by 26
Zhou, B., Li, H., Xing, C., Ye, H., Feng, J., Wu, J., Lu, Z., Fang, J., & Gao, S. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.022 · Cited by 26
Development of a peptide-based inducer of protein degradation targeting NOTCH1
Ohoka, N., Misawa, T., Kurihara, M., Demizu, Y., & Naito, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.011 · Cited by 26
YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Minas, T. Z., Han, J. J., Javaheri, T., Hong, S.-H., Schlederer, M., Saygıdeğer, Y., Çelik, H., Mueller, K. M., Temel, I., Özdemirli, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5520 · Cited by 25
Bashkin, J. K., Aston, K. W., Ramos, J. P., Koeller, K. J., Nanjunda, R. K., He, G., Dupureur, C. M., & Wilson, W. D. (2012) · Biochimie · doi:10.1016/j.biochi.2012.09.023 · Cited by 25
White, C. M., Heidenreich, O. T., Nordheim, A., & Beerman, T. A. (2000) · Biochemistry · doi:10.1021/bi001427l · Cited by 25
The GANT61, a GLI Inhibitor, Induces Caspase-Independent Apoptosis of SK-N-LO Cells
Μatsumoto, T., Tabata, K., & Suzuki, T. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00920 · Cited by 25
Uboldi, S., Bernasconi, S., Romano, M., Marchini, S., Nerini, I. F., Damia, G. L. M., Ganzinelli, M., Marangon, E., Sala, F., Clivio, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26340 · Cited by 24
Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide
Hochhauser, D., Kotecha, M., O’Hare, C. C., Morris, P. J., Hartley, J. M., Taherbhai, Z., Harris, D., Forni, C., Mantovani, R., Lee, M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0503 · Cited by 24
Mysore, V. S., Szablowski, J. O., Dervan, P. B., & Frost, P. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0361 · Cited by 24
Yeates, C. L. (2003) · PubMed · Cited by 24
VonHandorf, A., Sánchez-Martín, F. J., Biesiada, J., Zhang, H., Zhang, X., Medvedovic, M., & Puga, A. (2018) · Epigenetics · doi:10.1080/15592294.2018.1454243 · Cited by 24
Kiesslich, T., Mayr, C., Wachter, J., Bach, D., Fuereder, J., Wagner, A., Alinger, B., Pichler, M., Fazio, P. D., Ocker, M., et al. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2161-9 · Cited by 23
Wang, Z., Zhang, Z., Wu, Y., Chen, L., Luo, Q., Zhang, J., Chen, J., Luo, Z., Huang, X., & Cheng, Y. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.10.070 · Cited by 23
Kašpárková, J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh896 · Cited by 23
Solution-phase synthesis and biological evaluation of triostin A and its analogues
Hattori, K., Koike, K., Okuda, K., Hirayama, T., Ebihara, M., Takenaka, M., & Nagasawa, H. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob02505b · Cited by 23
GLI1, a master regulator of the hallmark of pancreatic cancer
Kasai, K. (2016) · Pathology International · doi:10.1111/pin.12476 · Cited by 23
A genetically selected cyclic peptide inhibitor of BCL6 homodimerization
Osher, E. L., Castillo, F., Elumalai, N., Waring, M. J., Pairaudeau, G., & Tavassoli, A. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.012 · Cited by 23
Weber, A., Borghouts, C., Brendel, C., Moriggl, R., Delis, N., Brill, B., Vafaizadeh, V., & Groner, B. (2015) · Cancers · doi:10.3390/cancers7010503 · Cited by 22
Kim, H. S., Kim, T., Ko, H., Lee, J., Kim, Y. S., & Suh, Y. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.036 · Cited by 22
Logotheti, S., Michalopoulos, I., Sideridou, M., Daskalos, A., Κοσσίδα, Σ., Spandidos, D. A., Field, J. K., Vojtesek, B., Liloglou, T., Gorgoulis, V. G., et al. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07710.x · Cited by 21
Wallbrecher, R., Chêne, P., Ruetz, S., Stachyra, T., Vorherr, T. E., & Brock, R. E. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13834 · Cited by 21
Novel approaches to targeting BRD4
Kharenko, O. A., & Hansen, H. C. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.10.003 · Cited by 21
Ghezali, L., Liagre, B., Limami, Y., Beneytout, J., & Leger, D. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095016 · Cited by 20
An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors
Szablowski, J. O., Raskatov, J. A., & Dervan, P. B. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0719 · Cited by 20
ZBP-89 and Sp1 contribute to Bak expression in hepatocellular carcinoma cells
Kong, X., Xu, P., Cai, W., Wang, H.-G., Li, B., Huang, G., He, Z., Chen, G., & Ye, C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4349-y · Cited by 19
Takahashi, R., Yamagishi, M., Nakano, K., Yamochi, T., Yamochi, T., Fujikawa, D., Nakashima, M., Tanaka, Y., Uchimaru, K., Utsunomiya, A., et al. (2014) · Cancer Science · doi:10.1111/cas.12480 · Cited by 18
Kašpárková, J., Thibault, T., Kostrhunová, H., Štěpánková, J., Vojtı́šková, M., Muchová, T. R., Midoux, P., Malinge, J., & Brabec, V. (2014) · FEBS Journal · doi:10.1111/febs.12711 · Cited by 18
Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors
Daka, P., Liu, A., Karunaratne, C. V., Csatary, E. E., Williams, C., Xiao, H., Lin, J., Xu, Z., Page, R. C., & Wang, H. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.025 · Cited by 18
Wang, L. G., & Ferrari, A. C. (2006) · PubMed Central · Cited by 17
Massaad-Massade, L., Navarro, S., Krummrei, U., Reeves, R., Beaune, P. H., & Barouki, R. (2002) · Biochemistry · doi:10.1021/bi011455j · Cited by 17
Vakili, H., Jin, Y., & Cattini, P. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380949 · Cited by 17
Accessible chromatin structure permits factors Sp1 and Sp3 to regulate human TGFBI gene expression
Lee, J.-J., Park, K., Shin, M. H., Yang, W.-J., Song, M.-J., Park, J.-H., Yong, T., Kim, E. K., & Kim, H. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.127 · Cited by 17
Flajollet, S., Rachez, C., Ploton, M., Schulz, C., Gallais, R., Métivier, R., Pawlak, M., Leray, A., Issulahi, A. A., Héliot, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064880 · Cited by 17
Mishra, R., Watanabe, T., Kimura, M., Koshikawa, N., Ikeda, M., Uekusa, S., Kawashima, H., Wang, X., Igarashi, J., Choudhury, D., et al. (2015) · Cancer Science · doi:10.1111/cas.12610 · Cited by 17
ERG expression in prostate cancer: biological relevance and clinical implication
Abou–Ouf, H., Zhao, L., & Bismar, T. A. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2096-x · Cited by 17
Transcriptional Regulation of Frizzled-1 in Human Osteoblasts by Sp1
Yu, S., Yerges-Armstrong, L. M., Chu, Y., Zmuda, J. M., & Zhang, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163277 · Cited by 17
LEF-1 recognition of platinated GG sequences within double-stranded DNA. Influence of flanking bases
Chválová, K., Sari, M., Bombard, S., & Kozelka, J. (2007) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.08.006 · Cited by 16
Sharma, A. K., Allam, R., Ray, R., & Rajeswari, M. R. (2009) · DNA and Cell Biology · doi:10.1089/dna.2009.0851 · Cited by 16
Bruice, T. C., Sengupta, D., Blaskó, A., Chiang, S.-Y., & Beerman, T. A. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(97)00011-4 · Cited by 16
Carretta, M., Brouwers-Vos, A. Z., Bosman, M. C. J., Horton, S. J., Martens, J. H. A., Vellenga, E., & Schuringa, J. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189102 · Cited by 16
Talib, J., Beck, J. L., Urathamakul, T., Nguyen, C. D., Aldrich-Wright, J. R., Mackay, J. P., & Ralph, S. F. (2009) · Chemical Communications · doi:10.1039/b904751d · Cited by 15
Transcriptional Control and the Ubiquitin–Proteasome System
Leung, A., Geng, F., Daulny, A., Collins, G. A., Guzzardo, P. M., & Tansey, W. P. (2008) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2008_102 · Cited by 14
Dang, X., Zeng, X., Coimbra, R. S. M., Eliceiri, B. P., & Baird, A. (2017) · Gene · doi:10.1016/j.gene.2017.08.041 · Cited by 14
β-Alanine and N-terminal cationic substituents affect polyamide–DNA binding
Liu, B., Wang, S., Aston, K. W., Koeller, K. J., Kermani, S. F. H., Castañeda, C. H., Scuderi, M. J., Luo, R., Bashkin, J. K., & Wilson, W. D. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02513k · Cited by 14
Jun, D. Y., Lee, J. Y., Park, H. S., Lee, Y. H., & Kim, Y. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189698 · Cited by 14
Senter, T. J., Gogliotti, R. D., Han, C., Locuson, C. W., Morrison, R. D., Daniels, J. S., Cierpicki, T., Grembecka, J. E., Lindsley, C. W., & Stauffer, S. R. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.026 · Cited by 13
Inami, M., Fukushima, A., Ueno, T., Yamada, T., Tsunemi, A., Matsumoto, Y., Fukuda, N., Soma, M., & Moriyama, M. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00328 · Cited by 12
Ishiwata, T., Iwasawa, S., Ebata, T., Fan, M., Tada, Y., Tatsumi, K., & Takiguchi, Y. (2018) · Oncology Reports · doi:10.3892/or.2018.6183 · Cited by 12
Small molecule inhibition of FOXM1: How to bring a novel compound into genomic context
Marsico, G., & Gormally, M. V. (2014) · Genomics Data · doi:10.1016/j.gdata.2014.10.012 · Cited by 11
Fancher, A. T., Hua, Y., Camarco, D. P., Close, D. A., Strock, C. J., & Johnston, P. A. (2016) · Assay and drug development technologies · doi:10.1089/adt.2016.741 · Cited by 11
Ji, P., Yuan, C., Ma, S., Fan, J., Fu, W., & Qiao, C. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.09.070 · Cited by 11
Mihara, N., Chiba, T., Yamaguchi, K., Sudo, H., Yagishita, H., & Imai, K. (2016) · Gene · doi:10.1016/j.gene.2016.12.002 · Cited by 8
Chen, W., Li, D., Wang, Z., Xu, X., Zhang, X., Jiang, Z., Guo, X., & You, Q. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.11.018 · Cited by 8
Reddy, A., Huang, C., Liu, H., DeLisi, C., Nevalainen, M. T., Szalma, S., & Bhanot, G. (2010) · International Conference on Genome Informatics (GIW) · doi:10.1142/9781848166585_0012 · Cited by 7
Dos-Santos, O., Lagarde, P., Pérot, G., Chibon, F., Ratet, N., Flamand, O., & Debüssche, L. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)71633-7 · Cited by 3
Cited by
Epigenetic mechanisms in breast cancer therapy and resistance
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 458
Therapeutic strategies targeting FOXO transcription factors
Calissi, G., Lam, E. W.-F., & Link, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0088-2 · Cited by 330
The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials
Peng, J., Yang, S., Ng, C. S. H., & Chen, G. G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108333 · Cited by 21
Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Shao, J., Yan, Y., Ding, D., Wang, D., He, Y., Pan, Y., Yan, W., Kharbanda, A., Li, H.-Y., & Huang, H. (2021) · doi:10.1101/2021.03.08.434493 · Cited by 2
Metadata
- Authors
- Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-06-19
- Volume
- 23
- Issue
- 6
- Pages
- 1479
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2809413985
- Cited by
- 352
- References
- 377
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.